Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era

Show other versions (1)

<h4>Background</h4> Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab (T/C) received Emergency Use Authorization (EUA) based on results of a clinical trial conducted prior to the emergence of the Omicron variant. The clinical effectiveness of T/C has not been well describ...

Full description

Bibliographic Details
Main Authors: Benjamin Chen, Nina Haste, Nancy Binkin, Nancy Law, Lucy E. Horton, Nancy Yam, Victor Chen, Shira Abeles
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138227/?tool=EBI

Similar Items

Similar Items